Alcohol-induced hepatic secretome identifies the FSTL3–activin A–ActRII axis as a therapeutic target in alcohol-related liver disease

Background Alcohol-related liver disease (ALD) is a leading cause of advanced liver disease yet has no effective medical therapies, making it unique among prevalent and morbid liver diseases. Objective We aimed to identify novel therapeutic targets for ALD by integrating human serum proteomics with the alcohol-induced hepatic secretome in mice. Design We analysed human serum proteomics and the alcohol-induced hepatic secretome across mouse models of ALD to identify candidate therapeutic targets which converged on follistatin-like 3 (FSTL3), an activin A antagonist. FSTL3 expression was characterised in mouse liver, human liver organoids and across the spectrum of human ALD. Single-cell and spatial transcriptomics were used to identify its cellular source. Its functional role was tested using hepatic FSTL3 overexpression and knockout mouse models, and the underlying mechanism was examined in cellular systems. Three clinical-stage therapeutics targeting different nodes of the activin A–ActRII pathway were evaluated in ALD: garetosmab (anti-activin A), sotatercept (ActRIIA-Fc) and bimagrumab (anti-ActRIIA/B). Results Integrative analysis identified FSTL3, a secreted TGF-β superfamily inhibitor not previously implicated in ALD. FSTL3 was induced by ethanol in mouse liver, human liver organoids and across the spectrum of human ALD, with activated hepatic stellate cells identified as its source. FSTL3 overexpression attenuated, whereas knockout aggravated the liver’s histological and transcriptional response to ethanol. Mechanistically, ethanol induced hepatocyte-autonomous secretion of activin A, which signalled through ActRII to induce p21, an axis neutralised by FSTL3. Garetosmab, sotatercept and bimagrumab each phenocopied FSTL3’s protective effect and prevented ethanol-dependent p21 induction. Conclusion The FSTL3–activin A–ActRII axis is a protective, druggable pathway in ALD, providing a rationale for repurposing existing clinical-stage therapeutics for a disease with no effective treatment.

Authors

Institutions

Publication Details

Journal
Gut
Published
2026-11-12
DOI
https://doi.org/10.1136/gutjnl-2026-340224
Primary Topic
Alcohol Consumption and Health Effects
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Alcohol-induced hepatic secretome identifies the FSTL3–activin A–ActRII axis as a therapeutic target in alcohol-related liver disease

Angela R. Shih, Russell P. Goodman, Sudha B. Biddinger, Andrew MacGregor Cameron et al.
Gut
Alcohol Consumption and Health Effects
article

Alcohol-induced hepatic secretome identifies the FSTL3–activin A–ActRII axis as a therapeutic target in alcohol-related liver disease

Angela R. Shih, Russell P. Goodman, Sudha B. Biddinger, Andrew MacGregor Cameron, Esperance A. K. Schaefer, Gloria Álvarez‐Sola, Nahid Arghiani, Jay Luther, Raymond Chung, Wei Zhang, Alan Mullen, Emma Butler, Zhaoli Sun, Melissa Brown, Kaihua Liu
article en

Abstract

Background Alcohol-related liver disease (ALD) is a leading cause of advanced liver disease yet has no effective medical therapies, making it unique among prevalent and morbid liver diseases. Objective We aimed to identify novel therapeutic targets for ALD by integrating human serum proteomics with the alcohol-induced hepatic secretome in mice. Design We analysed human serum proteomics and the alcohol-induced hepatic secretome across mouse models of ALD to identify candidate therapeutic targets which converged on follistatin-like 3 (FSTL3), an activin A antagonist. FSTL3 expression was characterised in mouse liver, human liver organoids and across the spectrum of human ALD. Single-cell and spatial transcriptomics were used to identify its cellular source. Its functional role was tested using hepatic FSTL3 overexpression and knockout mouse models, and the underlying mechanism was examined in cellular systems. Three clinical-stage therapeutics targeting different nodes of the activin A–ActRII pathway were evaluated in ALD: garetosmab (anti-activin A), sotatercept (ActRIIA-Fc) and bimagrumab (anti-ActRIIA/B). Results Integrative analysis identified FSTL3, a secreted TGF-β superfamily inhibitor not previously implicated in ALD. FSTL3 was induced by ethanol in mouse liver, human liver organoids and across the spectrum of human ALD, with activated hepatic stellate cells identified as its source. FSTL3 overexpression attenuated, whereas knockout aggravated the liver’s histological and transcriptional response to ethanol. Mechanistically, ethanol induced hepatocyte-autonomous secretion of activin A, which signalled through ActRII to induce p21, an axis neutralised by FSTL3. Garetosmab, sotatercept and bimagrumab each phenocopied FSTL3’s protective effect and prevented ethanol-dependent p21 induction. Conclusion The FSTL3–activin A–ActRII axis is a protective, druggable pathway in ALD, providing a rationale for repurposing existing clinical-stage therapeutics for a disease with no effective treatment.

Gut
Broad Institute (US), Boston Children's Hospital (US), Johns Hopkins University (US), University of Massachusetts Chan Medical School (US), University of Saint Joseph (US), Johns Hopkins Medicine (US), Mass General Brigham (US)
Burroughs Wellcome Fund, National Institute of Diabetes and Digestive and Kidney Diseases
Good health and well-being
Alcohol Consumption and Health Effects
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon